Answers by TheMediTary.Com - Last updated: 13-Jul-2023
Vosevi (sofosbuvir, velpatasvir and voxilaprevir) is FDA-approved for the treatment of adults with chronic hepatitis C virus (HCV) of two types:
- genotype 1, 2, 3, 4, 5, or 6 infection previously treated with an NS5A inhibitor regimen, or
- genotype 1a or 4 infection previously treated with a sofosbuvir regimen without an NS5A inhibitor.
Vosevi is supplied as tablets containing sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg. The recommended course of treatment for HCV in adults without cirrhosis, or with compensated cirrhosis, is one tablet daily for 12 weeks.